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The US Congress passed the Food and Drug Administration
Modernization Act and Amendments Act, mandating that in-
vestigators post protocols and the results of all clinical studies
enrolling human subjects in the United States in the trial registry
clinicaltrials.gov within 1 year after study completion [1,2]. Spon-
sors and principal investigators who do not comply with the federal
law are subject to ﬁnancial penalties up to $10,000/day for failing to
register or submit the results of trials. Numerous previous analyses
suggested poor compliance with this policy [3e6]. However, pre-
vious analyses were not able to precisely identify studies' applica-
bility to federal law, because this information is not in the publicly
available Web version of the trial registry, clinicaltrials.gov [4,7].
The Aggregate Analysis of ClincalTrials.gov (AACT) database
enabled us to analyze the entire set of registered studies and pre-
cise information about studies' applicability to federal law. We
aimed to investigate sponsor compliance with federal law to post
complete high-quality information about study and participant
characteristics and outcomes. We assumed noncompliance when
sponsors did not post the results or posted ambiguous data. The law* Corresponding author. Evidence-Based Medicine Quality Assurance, Elsevier,
1600 JFK Blvd 20th ﬂoor, Philadelphia, PA 19103, USA.
E-mail address: t.shamliyan@elsevier.com (T.A. Shamliyan).
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2451-8654/© 2016 The Authors. Published by Elsevier Inc. This is an open access article uclearly states a sponsor's responsibility for posting timely, com-
plete, and accurate information about the study, sponsors, in-
vestigators, and participants [1,2]. Therefore, we assumed sponsor
responsibility was the sole reason and did not speculate on other
reasons for not posting information about studies labeled by reg-
istry administrators as “applicable clinical trial.” We analyzed
sponsorship, conﬂict of interest, study design and risk of bias, and
reporting of participants' ﬂow and baseline demographics based on
provided information in the database extracts from the Clinical
Trials Transformation Initiative (CTTI) (https://www.ctti-
clinicaltrials.org/aact-database).2. Methods
We downloaded, reformatted, and analyzed all studies available
in the CTTI database as of May 2016 in the HPCC platform (High-
Performance Computing Cluster, https://hpccsystems.com/). The
CTTI database has 2 variables indicating whether a study is an
“applicable clinical trial” as deﬁned in US Public Law 110-85, Title
VIII, Section 801 and whether a trial is a Food and Drug Admin-
istrationeregulated intervention (Appendix Table 2). We relied on
straightforward law language regarding sponsor responsibility for
compliance. Therefore, in contrast with previous publications, we
did not speculate or hypothesize what other factors can result in
missing or ambiguous data [3,5,8].
We conducted frequency analysis of all ﬁelds required by the
World Health Organization for the registration of clinical studies
(Appendix Table 1). We identiﬁed clinical trials and conducted
frequency analysis of the ﬁelds describing study sponsorship,
conﬂict of interest by principal investigators, risk of bias in
study design, and the reporting of participants' ﬂow and base-
line demographics. We also analyzed reporting of all mandatory
ﬁelds required by the federal law (Appendix Table 2). For each
study applicable to Section 801, we calculated proportions of
missing data among all mandatory ﬁelds required by federal
law.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rules to detect missing data or inconsistencies in the data elements
[9]. However, this methodology has limitations, including the lack
of an independent source of study data to verify each data element
[9]. As stated by the registry director, “posting does not guarantee
that the record is fully compliant with either ClinicalTrials.gov or
legal requirements.” [9] We detected missing or ambiguous data
but did not contact the institutional review boards to conﬁrm the
accuracy of the data in ClinicalTrials.gov.
Following the federal ﬁnancial disclosure guidance [10], we
concluded that there was a conﬂict of interest when study sponsors
were employers of principal investigators. We categorized study
funding by industry for all studies funded by pharmaceutical or
device companies exclusively or in combination with individuals,
universities, or community-based organizations.
We deﬁned high risk of bias in study design according to the
criteria outlined by the Agency for Healthcare Research and Quality,
including termination status, non-random allocation of study
subjects, and open allocation status [11].
We identiﬁed all completed studies that did not post results on
clinicaltrials.gov in compliance with federal law (Section 801 and
criteria without posted results). We estimated the fee for noncom-
pliance with federal law as a minimum $1/day up to a maximum
$10,000/day for all days between the primary completion day and
the end of 2014. We excluded from the cost-analysis studies
completed in 2015e2016 to address a possible time lag between
posting the results on the Web and in the downloadable database.
3. Results
Wedownloaded 217,258 studies from the database in the formatTable 1
Sponsorship, conﬂict of interest, risk of bias, and reporting of participant's ﬂow and baselin
85 to post the results in clinicaltrials.gov.
Study characteristics
Applicable clinical trial as deﬁned in US Public Law 110-85, Title VIII, Section 801
Industry involvement in sponsoring the study
Principal investigators are employed by sponsoring organization
Principal investigators are not employed by sponsoring organization
Employment of principals investigators by sponsoring organization is not reported
Risk of bias
Allocation of subjects: randomized
Allocation of subjects: non-random
Allocation of subjects not reported
Terminated
Double-blind study
Open Label study
Single Blind study
Masking not reported
Study design
Phase not reported
Phase 0
Phase 1
Phase 1/Phase 2
Phase 2
Phase 2/Phase 3
Phase 3
Phase 4
Participants ﬂow
Reported attrition ( # of subjects not completed the study)
Reported study discontinuation due to adverse effects
Baseline patient characteristics
Reported baseline age of enrolled patients
Both genders enrolled
Female studies
Male studies
Gender not reported
Reported # of Asian patients
Reported # of African-American patients
Reported # of Hispanic patients
Reported # of Native American patientsof related tables. We linked all related tables by unique study,
treatment, and outcome identiﬁers. We were able to analyze
211,437 studies. We identiﬁed 44,635 studies applicable to Section
801 (Table 1). Industry was involved in sponsoring 63% of these
studies. The majority of the studies (75%) did not report employ-
ment of principal investigators by a sponsoring organization, and
obvious conﬂict of interest was identiﬁed in 4% of the studies in
which principal investigators were employed by sponsoring orga-
nizations (Table 1). The majority of the studies were randomized
clinical trials (60%), but only 38% of all studies applicable to Section
801 were double-blind studies. More than 3000 studies (9%)
applicable to Section 801 were terminated, mostly due to poor
recruitment. Information about attrition of study subjects (18%) and
treatment discontinuation due to adverse effects (8%) was available
only in a small proportion of studies (Table 1). Baseline participant
agewas available only in 18% of studies, and enrollment of racial and
ethnic minorities was available in less than 5% of studies (Table 1).
We identiﬁed 29,992 applicable clinical trials (according to
Section 801) that did not post results on clinicaltrials.gov. We
restricted our analysis to 14,476 studies completed before 2015 that
failed to post results in clinicaltrials.gov and therefore did not
comply with federal law (Fig. 1). These 14,476 studies enrolled
3,660,385 participants. The results from 12,479 studies have not
been published in journals; therefore, they are unavailable to the
public. We estimated that the penalty of noncompliance would be
from aminimum of $28.6 million to amaximum of $286 billion. We
identiﬁed 22 sponsors that failed to post the results from >50
studies each (the list is available upon request). The majority of
noncomplying studies were industry-sponsored (65.4%) random-
ized clinical trials (67.5%).e demographic information in studies that must comply with the US Public Law 110-
Number of studies % of total applicable studies
44,635
27,995 62.7
1910 4.3
9325 20.9
33,400 74.8
26,635 59.7
5526 12.4
12,474 27.9
3789 8.5
17,089 38.3
22,748 51.0
2357 5.3
2441 5.5
6998 15.7
292 0.7
3890 8.7
3063 6.9
14,534 32.6
1051 2.4
9553 21.4
5254 11.8
8133 18.2
3366 7.5
8218 18.4
38,379 86.0
3782 8.5
1855 4.2
619 1.4
1918 4.3
1928 4.3
486 1.1
1481 3.3
Fig. 1. The number of the studies that did not comply with the federal US Public Law 110-85, Title VIII, Section 801about posting the results in clinicaltrials.gov by the primary
completion dates as reported in clinicaltrials.gov (only studies completed before 2015 are included).
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In concordance with multiple previous publications, our ﬁnd-
ings indicated poor compliance with the federal law requiring
certain studies to make results available [3,5,8]. There are several
ongoing policy improvement efforts, including the Trial and
Experimental Studies Transparency (TEST) Act, National Institutes
of Health (NIH) policy, and growing public discussion about
emergent need in sharing of clinical trial results [12e14]. The NIH
recently issued a ﬁnal policy mandating the registration and
posting of the results of all NIH-funded clinical trials regardless of
coverage by the Food and Drug Administration Amendments Act
requirements [15]. The ﬁnal rule is expected to promote public trust
in clinical research, to fulﬁll an ethical obligation to the public and
trial participants, to optimize the public investment in research,
and to ensure accountability via the public reporting of information
[16]. Much better enforcement is needed. Lack of accountability
mechanisms result in enormous reporting bias in evidence analyses
that inform policy, coverage, and clinical decisions [17,18]. Policy
efforts must address enrollment of racial and ethnic minorities and
members of other underrepresented populations including elderlypeople, children, and women.
Our study has several limitations. We relied on information
submitted by principal investigators and did not contact sponsors
or investigators requesting submission of the missing data. We
relied on the trial registry for identiﬁcation of applicable studies
and assumed noncompliance when the results were not available
or ambiguous. We projected ranges of ﬁnancial penalties and found
no publicly available evidence of sponsor payments in cases of
delayed posting.
Nevertheless, our analysis demonstrates a clear need for better
accountability from sponsors and investigators who do not comply
with the federal law about posting results in clinicaltrials.gov. The
ﬁnal rule estimated an additional cost of $56 million for the public
and the sponsors related to study registration and the posting of
results [16]. However, modern technology (http://www.lexisnexis.
com/risk/) allows harmonization of institutional review board da-
tabases with trial registries. This harmonizationwill allow sponsors
to submit study information once, providing instant analysis of
compliance and the ability to check the quality control of the data
as it is entered.
Appendix Table 1
(at http://www.who.int/ictrp/network/trds/en/index.html).
The minimum amount of trial information that must appear in a register in order for a given trial to be considered fully registered.
There are currently 20 items in the WHO Trial Registration Data Set. It is sometimes referred to as the TRDS.
1. Primary Registry and Trial Identifying Number
Name of Primary Registry, and the unique ID number assigned by the Primary Registry to this trial.
2. Date of Registration in Primary Registry
Date the trial was ofﬁcially registered in the Primary Registry.
3. Secondary Identifying Numbers
Other identiﬁers, if any allocated by the Primary Registry. These include:
 The Universal Trial Number (UTN)
 Identiﬁers assigned by the sponsor (record Sponsor name and Sponsor-issued trial number (e.g. protocol number))
 Other trial registration numbers issued by other Registries (both Primary and Partner Registries in the WHO Registry Network, and other registries)
 Identiﬁers issued by funding bodies, collaborative research groups, regulatory authorities, ethics committees/institutional review boards, etc.<listbend>
All secondary identiﬁers will have 2 elements: an identiﬁer for the issuing authority (e.g. NCT, ISRCTN, ACTRN) plus a number.
There is no limit to the number of secondary identiﬁers that can be provided.
4. Source(s) of Monetary or Material Support
Major source(s) of monetary or material support for the trial (e.g. funding agency, foundation, company, institution).
5. Primary Sponsor
The individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or ﬁnancing a study. The Primary Sponsor is
responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder.
6. Secondary Sponsor(s)
Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship.
A secondary sponsor may have agreed to:
 take on all the responsibilities of sponsorship jointly with the primary sponsor; or
 form a group with the Primary Sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or
 act as the Primary Sponsor's legal representative in relation to some or all of the trial sites.
7. Contact for Public Queries
Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status.
8. Contact for Scientiﬁc Queries
There must be clearly assigned responsibility for scientiﬁc leadership to a named Principal Investigator (PI). The PI may delegate responsibility for dealing with
scientiﬁc enquiries to a scientiﬁc contact for the trial. This scientiﬁc contact will be listed in addition to the PI.
The contact for scientiﬁc queries must therefore include:
 Name and title, email address, telephone number, postal address and afﬁliation of the Principal Investigator, and;
 Email address, telephone number, postal address and afﬁliation of the contact for scientiﬁc queries about the trial (if applicable). The details for the scientiﬁc contact
may be generic (that is, there does not need to be a named individual): e.g. a generic email address for research teammembers qualiﬁed to answer scientiﬁc queries.
9. Public Title
Title intended for the lay public in easily understood language.
10. Scientiﬁc Title
Scientiﬁc title of the study as it appears in the protocol submitted for funding and ethical review. Include trial acronym, if available.
11. Countries of Recruitment
The countries from which participants will be, are intended to be, or have been recruited at the time of registration.
12. Health Condition(s) or Problem(s) Studied
Primary health condition(s) or problem(s) studied (e.g., depression, breast cancer, medication error).
If the study is conducted in healthy human volunteers belonging to the target population of the intervention (e.g. preventive or screening interventions), enter the
particular health condition(s) or problem(s) being prevented.
13. Intervention(s)
For each arm of the trial record a brief intervention name plus an intervention description.
Intervention Name: For drugs use generic name; for other types of interventions provide a brief descriptive name.
 For investigational new drugs that do not yet have a generic name, a chemical name, company code or serial number may be used on a temporary basis. As soon as
the generic name has been established, update the associated registered records accordingly.
 For non-drug intervention types, provide an intervention name with sufﬁcient detail so that it can be distinguished from other similar interventions.
Intervention Description: Must be sufﬁciently detailed for it to be possible to distinguish between the arms of a study (e.g. comparison of different dosages of drug)
and/or among similar interventions (e.g. comparison of multiple implantable cardiac deﬁbrillators). For example, interventions involving drugs may include dosage
form, dosage, frequency and duration.
If the intervention is one or more drugs then use the International Non-Proprietary Name for each drug if possible (not brand/trade names). For an unregistered
drug, the generic name, chemical name, or company serial number is acceptable.
If the intervention consists of several separate treatments, list them all in one line separated by commas (e.g. “low-fat diet, exercise”).
For controlled trials, the identity of the control arm should be clear. The control intervention(s) is/are the interventions against which the study intervention is
evaluated (e.g. placebo, no treatment, active control). If an active control is used, be sure to enter in the name(s) of that intervention, or enter “placebo” or “no
treatment” as applicable. For each intervention, describe other intervention details as applicable (dose, duration, mode of administration, etc).
14. Key Inclusion and Exclusion Criteria
Inclusion and exclusion criteria for participant selection, including age and sex. Other selection criteria may relate to clinical diagnosis and co-morbid conditions;
exclusion criteria are often used to ensure patient safety.
If the study is conducted in healthy human volunteers not belonging to the target population (e.g. a preliminary safety study), enter “healthy human volunteer”.
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Appendix Table 1 (continued )
15. Study Type
Study type consists of:
 Type of study (interventional or observational)
 Study design including:
▪ Method of allocation (randomized/non-randomized)
▪ Masking (is masking used and, if so, who is masked)
▪ Assignment (single arm, parallel, crossover or factorial)
▪ Purpose
 Phase (if applicable)
For randomized trials: the allocation concealment mechanism and sequence generation will be documented.
16. Date of First Enrollment
Anticipated or actual date of enrolment of the ﬁrst participant.
17. Target Sample Size
Number of participants that this trial plans to enrol in total.
18. Recruitment Status
Recruitment status of this trial:
 Pending: participants are not yet being recruited or enrolled at any site
 Recruiting: participants are currently being recruited and enrolled
 Suspended: there is a temporary halt in recruitment and enrolment
 Complete: participants are no longer being recruited or enrolled
 Other
19. Primary Outcome(s)
Outcomes are events, variables, or experiences that are measured because it is believed that they may be inﬂuenced by the intervention.
The Primary Outcome should be the outcome used in sample size calculations, or the main outcome(s) used to determine the effects of the intervention(s). Most
trials should have only one primary outcome.
For each primary outcome provide:
 The name of the outcome (do not use abbreviations)
 The metric or method of measurement used (be as speciﬁc as possible)
 The timepoint(s) of primary interest
Example:
Outcome Name: Depression.
Metric/method of measurement: Beck Depression Score.
Timepoint: 18 weeks following end of treatment.
20. Key Secondary Outcomes
Secondary outcomes are outcomes which are of secondary interest or that are measured at timepoints of secondary interest. A secondary outcome may involve the
same event, variable, or experience as the primary outcome, but measured at timepoints other than those of primary interest.
As for primary outcomes, for each secondary outcome provide:
 The name of the outcome (do not use abbreviations)
 The metric or method of measurement used (be as speciﬁc as possible)
 The timepoint(s) of interest
Appendix Table 2
Deﬁnitions of the data elements that are available for downloading from www.clinicaltrials.gov (* mandatory ﬁelds required by the federal law).
Field name Deﬁnition of the data element Utilization in our analysis
NCT ID* The ClinicalTrials.gov identiﬁer Unique study identiﬁer
Other IDs Other identiﬁcation numbers assigned to the protocol, including unique identiﬁers from
other registries and NIH grant numbers
Not used
Title* Ofﬁcial name of the protocol provided by the study principal investigator or sponsor Not used
Acronym Acronym or initials used to identify this study Not used
FDA Regulated
Intervention?
FDA Regulated Intervention? (FDAAA) Yes/No
Deﬁnition: Indicate whether this trial includes an intervention subject to US Food and
Drug Administration regulation under section 351 of the Public Health Service Act or any
of the following sections of the Federal Food, Drug and Cosmetic Act: 505, 510(k), 515,
520(m), and 522.
Analyzed
Is section 801? Section 801 Clinical Trial? (FDAAA) Yes/No
Deﬁnition: If this trial includes an FDA regulated intervention, indicate whether this is an
“applicable clinical trial” as deﬁned in US Public Law 110-85, Title VIII, Section 801.
Brieﬂy, applicable drug trials include controlled clinical investigations, other than Phase I
investigations, of a drug or biologic subject to US FDA regulation. Applicable device
clinical trials are controlled trials with health outcomes of devices subject to FDA
regulation, other than small feasibility studies, and pediatric postmarket surveillance.
Analyzed
Funded* Funding source as industry, NIH, U.S. Federal Government, Network, or other We categorized as industry funded or other funding
Sponsors* Name of primary organization that oversees implementation of study and is responsible
for data analysis
Analyzed
(continued on next page)
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Appendix Table 2 (continued )
Field name Deﬁnition of the data element Utilization in our analysis
Recruitment* # Enrolling by invitation: participants are being (or will be) selected from a
predetermined population
# Active, not recruiting: study is ongoing (i.e., patients are being treated or examined),
but participants are not currently being recruited or enrolled
# Completed: the study has concluded normally; participants are no longer being
examined or treated (i.e., last patient's last visit has occurred)
# Suspended: recruiting or enrolling participants has halted prematurely but
potentially will resume
# Terminated: recruiting or enrolling participants has halted prematurely and will not
resume; participants are no longer being examined or treated
# Withdrawn: study halted prematurely, prior to enrollment of ﬁrst participant
We used the exact categories as reported in trial registry
Conditions* Primary disease or condition being studied, or focus of the study. Diseases or conditions
should use the National Library of Medicine's Medical Subject Headings (MeSH)
controlled vocabulary when possible.
Normalized and analyzed
Study Types* Interventional or observational studies We used the exact categories as reported in trial registry
Study Designs Purpose, phase, treatment allocation, masking of the treatment status; type of primary
outcome or endpoint that the protocol is designed to evaluate
Analyzed
Phases* Phase of investigation, as deﬁned by the US FDA for trials involving investigational new
drugs
We used the exact categories as reported in trial registry
Study Results - Participant Flow
- Baseline Characteristics
- Outcome Measures and Statistical Analyses
- Adverse Events Information
- Administrative Information
“Applicable clinical trials” generally include interventional studies (with one or more
arms) of drugs, biological products, or devices that are subject to FDA regulation,
meaning that the trial has one ormore sites in the U.S, involves a drug, biologic, or device
that is manufactured in the US (or its territories), or is conducted under an
investigational new drug application (IND) or investigational device exemption (IDE).
We categorized the studies into 2 categories: with posted
results and without posted results.
We analyzed reporting of the number of participants who
completed studies and the number of participants who
discontinued the study due to adverse effects
Interventions* - Drug (including placebo)
- Device (including sham)
- Biological/Vaccine
- Procedure/Surgery
- Radiation
- Behavioral (e.g., Psychotherapy, Lifestyle Counseling)
- Genetic (including gene transfer, stem cell and recombinant DNA)
- Dietary Supplement (e.g., vitamins, minerals)
We categorized interventions as drug, procedure, radiation,
biologics, or behavioral according to the categories in
ClinicalTrials.gov
Outcome
Measures
Speciﬁc key measurement(s) or observation(s) used to measure the effect of
experimental variables in a study, or for observational studies, to describe patterns of
diseases or traits or associations with exposures, risk factors or treatment.
Not used
Gender* Physical gender of individuals who may participate in the protocol We used the exact categories as reported in trial registry
Age Groups Age of participants We used the exact categories as reported in trial registry
Enrollment* Number of subjects in the trial We used the reported numbers, excluding ambiguous values
e.g., enrollment values of more than 99,999 participants
registry
First Received Date the protocol information was received Not used
Start Date* Date that enrollment to the protocol begins We calculated the length of studies as the time period
between start and completion datesCompletion Date Final date on which data was (or is expected to be) collected
Last Updated Date the protocol information was updated Not used
Last Veriﬁed* Date the protocol information was last veriﬁed Not used
Primary
Completion
Date*
The date that the ﬁnal subject was examined or received an intervention for the
purposes of ﬁnal collection of data for the primary outcome, whether the clinical trial
concluded according to the prespeciﬁed protocol or was terminated
We calculated the length of studies as the time period
between start and primary completion date when completion
dates were missing.
Has Expanded
Access?*
Indicate whether any non-protocol access is to be provided for the investigational drug
or device. If so, an Expanded Access record should also be created for this IND/IDE.
Analyzed
Accepts Healthy
Volunteers?*
Indicate if persons who have not had the condition(s) being studied or otherwise related
conditions or symptoms, as speciﬁed in the eligibility requirements, may participate in
the study. Select Yes/No.
Analyzed
Maximum age* Maximum age of participants. Analyzed
Minimum age* Minimum age of participants. Analyzed
Organization's
Unique
Protocol id*
Unique identiﬁcation assigned to the protocol by the sponsoring organization, usually an
accession number or a variation of a grant number. Multiple studies conducted under the
same grant must each have a unique number.
Analyzed
Primary
Completion
Date Type*
A “Type” menu is also included, with options Anticipated and Actual. For active studies,
set Type to Anticipated and specify the expected completion date, updating the date as
needed over the course of the study. Upon study completion, change Type to Actual and
update the date if necessary.
Analyzed
Lead Sponsor or
Collaborators*
Name of primary organization that oversees implementation of study and is responsible
for data analysis. For applicable clinical trials, sponsor is deﬁned in 21 CFR
Analyzed
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